The choice of cytoreductive drug was decided by the treating physician considering patient preferences, but with a strong trend towards younger patients receiving peg‐IFN and older patients getting hydroxycarbamide.
← all excerpts
Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia.
1
—
—